Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 7/20 | 0.37 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22207410 | 0.84 | GAA (0.42) | GAAALDH1A1LMNAPOLBRET | |
| SCHEMBL20640604 | 0.78 | GAA (0.44) | GAAALDH1A1LMNAPOLBRET | |
| SCHEMBL21152701 | 0.74 | GAA (0.51) | GAAALDH1A1LMNAPOLBRET | |
| SCHEMBL31105919 | 0.72 | GAA (0.47) | GAAALDH1A1LMNAPOLBRET | |
| SCHEMBL17675453 | 0.72 | GAA (0.49) | GAAALDH1A1LMNAPOLBRET | |
| SCHEMBL21002088 | 0.72 | GAA (0.49) | GAAALDH1A1LMNAPOLBRET | |
| SCHEMBL3500980 | 0.71 | ALDH1A1 (0.49) | GAAALDH1A1LMNAPOLBRET | |
| SCHEMBL31105864 | 0.71 | GAA (0.45) | GAAALDH1A1LMNAPOLBRET | |
| SCHEMBL31105972 | 0.71 | GAA (0.45) | GAAALDH1A1LMNAPOLBRET | |
| SCHEMBL22207247 | 0.71 | GAA (0.36) | GAAALDH1A1LMNAPOLBRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626426-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND AT LEAST ONE OTHER THERAPEUTIC AGENT | JANSSEN Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4626427-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND A BCL-2 INHIBITOR | Janssen Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| US-20250302840-A1 | COMBINATION THERAPIES | JANSSEN-CILAG (FR) | 2025-10-02 | — | — | US | disclosed |
| CN-118845786-A | Combination therapy | 詹森药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118845787-A | Combination therapy | 詹森药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-114174278-B | Dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20240261292-A1 | COMBINATION THERAPIES | JANSSEN-CILAG (FR) | 2024-08-08 | — | — | US | disclosed |
| WO-2024114666-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND A BCL-2 INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024114664-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND AT LEAST ONE OTHER THERAPEUTIC AGENT | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| EP-4337215-A1 | COMBINATION THERAPIES | JANSSEN Pharmaceutica NV (BE) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022237719-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237719-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237720-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| US-20220298137-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2022-09-22 | — | — | US | disclosed |
| WO-2022074534-A1 | COMBINATIONS OF DIHYDROOROTATE DEHYDROGENASE INHIBITORS AND HYPOMETHYLATING AGENTS | JANSSEN BIOTECH, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-114174278-A | Dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3956320-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| WO-2020212897-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20200331881-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2020-10-22 | — | — | US | disclosed |
| WO-2020212897-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261292-A1 | COMBINATION THERAPIES | IDH3B, DHODH, IDH3A | GAA 4189/4885ALDH1A1 418/4885LMNA 1287/4885 |
| US-20250302840-A1 | COMBINATION THERAPIES | MEN1, MLLT1, BMI1 | GAA 4660/4885ALDH1A1 3293/4885LMNA 149/4885 |
| US-20220298137-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | GAA 270/4885ALDH1A1 116/4885LMNA 3592/4885 |
| US-20200331881-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | GAA 270/4885ALDH1A1 116/4885LMNA 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.